AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/16/22

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the ...

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2022 Earnings Conference Call May 10, 2022, 08:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications & Corporate Affairs Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief Financial Officer Max Cola...

The commercial-stage biotech, Aurinia Pharmaceuticals (NASDAQ:AUPH) is trading lower in the pre-market Tuesday despite reporting better than expected revenue for 1Q 2022 as the company pointed to COVID impact on sales for its lupus nephritis therapy, Lupkynis (voclosporin). Following its FDA ...

Aurinia Pharma press release (NASDAQ:AUPH): Q1 GAAP EPS of -$0.27 in-line. Revenue of $21.63M (+2276.9% Y/Y) beats by $2.39M. The company maintains net revenue guidance range of $115M-$135M from sales of LUPKYNIS for 2022 vs. consensus of $138.01M. For further details see: Aurinia Pharm...

$21.6 million in net revenue for Q1 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS for 2022 Continued increases in LUPKYNIS™ (voclosporin) Patients on Treatment and Patient Start Forms; Steady Conversion Rates and Payor Coverage ...

Aurinia Pharma (NASDAQ:AUPH) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open. The consensus EPS Estimate is -$0.27 (+32.5% Y/Y) and the consensus Revenue Estimate is $19.24M (+2014.3% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revision...

ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS, EBIX, ENOV, EOSE, EPC, EPZM, EVRI, FOX, FOXA, GMDA, H, HAE, HL, IAA, IGT, IIVI, IMUX, ITCI, JAGX, OTCPK:KEYUF, KNBE,...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter financial and operational results announcement on Tuesday, May 10, 2022. The new numbers for interested partici...

New York, New York--(Newsfile Corp. - May 6, 2022) - Levi & Korsinsky, LLP notifies investors in Aurinia Pharmaceuticals Inc. ("Aurinia Pharmaceuticals Inc." or the "Company") (NASDAQ: AUPH) of a class action securities lawsuit. The lawsuit on behalf of Aurinia Pharmaceuticals Inc. inve...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for first quarter 2022 on Tuesday, May 10, 2022, before markets open. Aurinia’s management team will host a ...